β-上腺阻断减弱了烧伤后脂肪组织的不良反应
Shayahati Bieerkehazhi1,2,3,4, Abdikarim Abdullahi2,3,4, Fadi Khalaf5,3,4
1Sunnybrook Research Institute, Toronto, ON, Canada.
概括
严重的烧伤损伤会破坏脂肪组织的新陈代谢. 作为β-阻断剂的普罗普拉诺洛尔有效地减少了内分泌网膜应激,脂解和白色脂肪组织在内脏和皮下脂肪储存中的色.
科学领域:
- 生物医学科学 生物医学科学
- 代谢研究研究 代谢研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的烧伤会引发长时间的超代谢状态,包括增加的能量消耗和代谢.
- 燃烧后持续升高的甲基荷胺会导致脂肪组织功能障碍,包括脂解和白色脂肪组织 (WAT) 色.
- 脂肪组织的不良变化可能会恶化高代谢反应和患者的结果,需要进行治疗干预.
研究的目的:
- 为了调查烧伤后的脂肪储存区特定的变化.
- 探索普拉诺洛尔在减轻不同脂肪储存中的烧伤引起的病理生理变化的治疗效果.
- 了解β-上腺受体阻塞对热损伤后脂肪组织代谢的影响.
主要方法:
- 利用热损伤的小鼠模型来诱导烧伤反应.
- 分析了脂肪组织储存 (表皮WAT和 inguinalWAT) 对于内质网膜 (ER) 应激和脂解途径激活.
- 用于评估它对燃烧引起的脂肪组织变化的影响,包括ER压力,脂解和UCP1介导的色.
主要成果:
- 烧伤诱导了 epididymal WAT 的 ER 压力,但不是 inguinal WAT,同时在两个仓库中激活了 lipolytic 途径.
- 普拉诺洛尔治疗缓解了 epididymal WAT 中的 ER 压力,并减少了内脏和皮下脂肪组织的脂解.
- 普罗巴诺洛尔的使用减弱了皮下WAT的燃烧诱导的UCP1-介导的色.
结论:
- 烧伤伤害导致内脏和皮下脂肪组织储存物中明显的代谢和压力相关的变化.
- 甲醇有效地减轻脂肪组织中因燃烧引起的不良变化,包括ER压力,脂毒性和WAT色.
- 布拉诺洛尔的β-上腺体阻塞代表了管理影响脂肪组织代谢的烧伤并发症的有前途的治疗策略.
相关概念视频
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
546
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
546
Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
564
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
564
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
837
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
837
Adrenergic Receptors (Adrenoceptors): Classification
2.4K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.4K


